Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link

Volume 27, Number 6—June 2021

Research Letter

Multisystem Inflammatory Syndrome in Adults after Mild SARS-CoV-2 Infection, Japan

Yasuhiro Yamada1Comments to Author , Kaoru Fujinami1, Tadashi Eguchi, Hiroshi Takefuji, and Nobuaki Mori
Author affiliations: National Hospital Organization Tokyo Medical Center, Tokyo, Japan (Y. Yamada, K. Fujinami, T. Eguchi, H. Takefuji, N. Mori); University College London, London, UK (K. Fujinami)

Main Article

Table

Laboratory studies performed at intensive care unit admission of patient with multisystem inflammatory syndrome after mild severe acute respiratory syndrome coronavirus 2 infection, Japan

Laboratory test Result Reference range
C-reactive protein, mg/dL 36.77 <0.14
Procalcitonin, ng/mL 3.67 <0.05
Interleukin 6, pg/dL 565 <4
Leukocyte count, × 109 cells/L 22.4 3.0–8.6
Neutrophil count, × 109 cells/L 21.0 1.5–5.8
Lymphocyte count, × 109 cells/L 1.0 1.0–3.0
Hemoglobin, g/dL 13.2 13.7–16.8
Platelets, × 109/L 180 158–348
Serum creatinine, mg/dL 2.54 0.65–1.07
Albumin, g/dL 2.5 4.1–5.1
Aspartate aminotransferase, U/L 19 13–30
Alanine aminotransferase, U/L 37 10–42
Ferritin, ng/mL 1563 17.9–464
Fibrinogen, mg/dL >900 200–400
D-dimer, ng/mL 5.7 <1
Creatine phosphokinase, U/L 37 59–248
Troponin T, ng/mL 0.861 <0.014
B-type natriuretic peptide, pg/mL >2000 <18.4

Main Article

1These authors contributed equally to this article.

Page created: April 05, 2021
Page updated: May 18, 2021
Page reviewed: May 18, 2021
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external